#2-59E. Expanding Pneumococcal Coverage: New ACIP Guidelines for Adults Aged 50 and Up (MMWR, 2025)

Do you find yourself routinely assessing complex risk conditions before recommending pneumococcal vaccination for patients in their 50s and early 60s? Before October 2024, the Advisory Committee on Immunization Practices (ACIP) primarily recommended pneumococcal conjugate vaccine (PCV) only for adults aged ≥65 years or those 19–64 years with specific risk conditions. This Morbidity and Mortality Weekly Report summarizes the evidence leading to the expansion of these age-based PCV recommendations, noting that adults aged 50–64 years experience high invasive pneumococcal disease (IPD) incidence and that persistent racial disparities in disease rates exist in this demographic. The most pivotal finding is the recommendation endorsing a single dose of PCV for all PCV-naïve adults aged 50 years and older, offering a streamlined approach to protection. This decision is expected to boost coverage and reduce morbidity, yet, when critically reviewing the economic models, it is essential to consider the acknowledged uncertainties regarding the duration of vaccine protection and the magnitude of indirect effects from pediatric vaccination. This report is crucial for clinicians as it establishes a clear, unified, age-based strategy for pneumococcal vaccination, simplifying the clinical decision-making process for a substantial segment of the adult patient population.

Citation: Kobayashi M, Leidner AJ, Gierke R, et al. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. Morbidity and Mortality Weekly Report. 74(1), 1–7, 2025. DOI: (None)

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.